ARNA Arena Pharmaceuticals Inc.

46.51
-0.46  -1%
Previous Close 46.97
Open 47.11
Price To Book 2.03
Market Cap 2,330,483,314
Shares 50,107,145
Volume 377,151
Short Ratio
Av. Daily Volume 361,211
Stock charts supplied by TradingView

NewsSee all news

  1. Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

    SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: Evercore ISI HealthCONx

  2. California Life Sciences Association Honors Arena Pharmaceuticals at the Pantheon 2019 DiNA™ Awards for the Deal of the Year

    SAN DIEGO, Nov. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was honored by the California Life Sciences Association (CLSA) with the Pantheon 2019 DiNA™ Deal of the Year Award. The Pantheon DiNA

  3. Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia

    NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for

  4. Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs

    SAN DIEGO, Nov. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2019. "Arena

  5. Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS

    SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented new data evaluating the human mass balance, metabolic disposition, and pharmacokinetics (PK) of etrasimod in healthy adult male

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved June 27, 2012.
Lorcaserin
Obesity
Phase 2/3 trial to be initiated 2019.
Olorinab (APD371)
Pain associated with Crohn's disease
Phase 3 commencement of dosing announced June 17, 2019.
Etrasimod - ELEVATE UC 52
Ulcerative colitis
Phase 3 ongoing. Licensed to UTHR November 15, 2018.
Ralinepag
Pulmonary Arterial Hypertension
Phase 2 commencement of dosing announced October 28, 2019. Data due 2H 2020.
Etrasimod
Atopic dermatitis (AD)
Phase 2b/3 trial to be initiated in 2019.
Etrasimod
Crohn's disease

Latest News

  1. Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

    SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that members of its senior management team will participate at the upcoming investor conferences: Evercore ISI HealthCONx

  2. California Life Sciences Association Honors Arena Pharmaceuticals at the Pantheon 2019 DiNA™ Awards for the Deal of the Year

    SAN DIEGO, Nov. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) was honored by the California Life Sciences Association (CLSA) with the Pantheon 2019 DiNA™ Deal of the Year Award. The Pantheon DiNA

  3. Everest Medicines Achieved First Patient Dosing Milestone in Etrasimod Phase 3 Clinical Study in Ulcerative Colitis Patients in Asia

    NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for

  4. Arena Reports Third Quarter Financial Results with Continued Progress on Clinical Programs

    SAN DIEGO, Nov. 7, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today provided a corporate update and reported financial results for the third quarter ended September 30, 2019. "Arena

  5. Arena Pharmaceuticals Presented New Data Highlighting the Human Mass Balance and Metabolism Profile of Etrasimod at AAPS

    SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented new data evaluating the human mass balance, metabolic disposition, and pharmacokinetics (PK) of etrasimod in healthy adult male

  6. Arena Pharmaceuticals to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that members of its senior management team will present at the upcoming investor conferences: Credit Suisse 28th Annual

  7. Arena Pharmaceuticals to Release Third Quarter 2019 Financial Results and Provide Corporate Update on November 7

    SAN DIEGO, Oct. 31, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will release its third quarter 2019 financial results and provide a corporate update on Thursday, November 7, 2019, after the close of

  8. Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis

    - ADVISE clinical trial initiated and enrollment progressing - Evaluating patients with the clinical diagnosis of moderate-to-severe atopic dermatitis - Significant unmet need for an oral therapy in atopic dermatitis

  9. Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community

    SAN DIEGO, Oct. 18, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will present new open-label extension data from the Phase 2 OASIS trial for its investigative drug candidate etrasimod, a

  10. Arena Pharmaceuticals Presented New Data from the Phase 2 OASIS trial for Etrasimod at the World Congress of Gastroenterology Meeting

    SAN DIEGO, Calif., Sept. 26, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented new data from the Phase 2 OASIS trial for etrasimod, an investigational, once-daily, oral, selective sphingosine

  11. Arena Pharmaceuticals to Present at the Cantor Global Healthcare Conference on October 2

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that Amit D. Munshi, President and Chief Executive Officer of Arena, will present a corporate update at the Cantor

  12. Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting

    SAN DIEGO, Sept. 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) will present new preclinical data for etrasimod, an investigational, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor

  13. Arena Pharmaceuticals Presented New Patient-Reported Outcomes Data for Olorinab at the European Society of Neurogastroenterology & Motility NeuroGASTRO 2019 Meeting

    SAN DIEGO, Sept. 9, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) presented new patient-reported outcomes data for olorinab, an investigational, oral, peripherally acting, highly-selective, full agonist

  14. Arena Pharmaceuticals to Participate in Upcoming Investor Conferences

    SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that members of its senior management team will participate in the upcoming investor conferences: Wells Fargo Global